Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome

Kinikanwo Green; Collins Amadi

doi:doi:10.11648/j.jgo.20210906.16

| Peer-Reviewed

Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome

Kinikanwo Green, Collins Amadi

Published in Journal of Gynecology and Obstetrics (Volume 9, Issue 6)

Received: 20 October 2021 Accepted: 8 November 2021 Published: 17 November 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (p<0.05). With worsening severity, there was an increasing trend of plasma creatinine and UA but a decreasing trend of albumin among the cHELLP variants (p<0.05). UA level exhibited the strongest positive correlation with PB, LDH, aspartate, and alanine aminotransferases and maintained the strongest negative correlation with platelet count among those with cHELLP variants (p<0.05). At a cut-off value of 1.5 mmol/L, plasma UA (AUC:0.968; 95%CI:0.913-1.000;p<0.001) level had the most robust ROC values compared to those of plasma creatinine and albumin among the cHELLP variants. Conclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.

Published in	Journal of Gynecology and Obstetrics (Volume 9, Issue 6)
DOI	10.11648/j.jgo.20210906.16
Page(s)	217-223
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

HELLP, Complete HELLP, Partial HELLP

References

[1]	Pritchard JA, Weisman R, Jr, Ratnoff OD, et al. Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med. 1954; 250: 89 – 98.
[2]	Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol. 2005; 193: 859.
[3]	Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) Am J Obstet Gynecol. 1993; 169:1000 – 6.
[4]	Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004; 103: 981 – 91.
[5]	Baxter JK, Weinstein L. HELLP syndrome: the state of the art. Obstet Gynecol Surv. 2004; 59: 838 – 45.
[6]	Deruelle P, Coudoux E, Ego A, et al. Risk factors for post-partum complications occurring after preeclampsia and HELLP syndrome. A study in 453 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol. 2006; 125: 59–65.
[7]	Raval DS, Co S, Reid MA, et al. Maternal and neonatal outcome of pregnancies complicated with maternal HELLP syndrome. J Perinatol. 1997; 17: 266 – 9.
[8]	Isler CM, Rinehart BK, Terrone DA, et al. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 1999; 181: 924 – 8.
[9]	Curtin WM, Weinstein L. A review of HELLP syndrome. J Perinatol. 1999; 19: 138 – 43.
[10]	Makinde ON, Adegoke OA, Adediran IA, et al. HELLP syndrome: the experience at Ile-Ife, Nigeria. J Obstet Gynaecol. 2009; 29 (3): 195-9.
[11]	Onuh SO, Aisien AO. Maternal and fetal outcome in eclamptic patients in Benin City, Nigeria. J Obstet Gynaecol. 2004; 24 (7): 765-8.
[12]	Tessema GA, Tekeste A, Ayele TA. Preeclampsia and associated factors among pregnant women attending antenatal care in Dessie referral hospital, Northeast Ethiopia: a hospital-based study. BMC Pregnancy Childbirth. 2015; 15: 73. doi: 10.1186/s12884-015-0502-7.
[13]	Lisonkova S, Bone JN, Muraca GM, Razaz N, Wang LQ, Sabr Y, et al. Incidence and risk factors for severe preeclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome, and eclampsia at preterm and term gestation: a population-based study. Am J Obstet Gynecol. 2021. Doi: http://doi.org/10.1016/j.ajog.2021.04.261
[14]	Tyas BD, Lestari P, Aldika Akbar MI. Maternal Perinatal Outcomes Related to Advanced Maternal Age in Preeclampsia Pregnant Women. J Family Reprod Health. 2019; 13 (4): 191-200.
[15]	Gong L, Zhao H, Cui Y, Li X. Transcriptome analysis of placentae reveals HELLP syndrome exhibits a greater extent of placental metabolic dysfunction than preeclampsia. Hypertens Pregnancy. 202; 40 (2): 134-43. doi: 10.1080/10641955.2021.1908348.
[16]	Wallace K, Harris S, Addison A, Bean C. HELLP Syndrome: Pathophysiology and Current Therapies. Curr Pharm Biotechnol. 2018; 19 (10): 816-26.
[17]	Ye W, Shu H, Yu Y, Li H, Chen L, Liu J, et al. Acute kidney injury in patients with HELLP syndrome. Nephrology. 2019; 51: 1199 – 206
[18]	Asghamia M, Mirblouk F, Kazemi S, Pourmarzi D, Keivani MM, Heirati SFD. Maternal serum uric acid and maternal and neonatal complications in preeclamptic women: A cross-sectional study. Int J Reprod Biomed. 2017; 15(9): 583 – 588.
[19]	Bellos I, Pergialiotis V, Loutradis D, Daskalakis G. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens. 2020; 22: 826 – 34.
[20]	Gedik E, Yucei N, Salin T, Koca E, Colak YZ, Togal T. Hemolysis, elevated liver enzymes, and low platelet syndrome: outcomes for patients admitted to intensive care at a tertiary referral hospital. Hypertens Pregnancy. 2017; 36 (1): 21-29.
[21]	Chen H, Tao F, Fang X, Wang X. Association of hypoproteinemia in preeclampsia with maternal and perinatal outcomes: A retrospective analysis of high-risk women. J Res Med Sci. 2016; 21; 98. Doi:10.4103/1735-1995.193170
[22]	Seong WJ, Chong GO, Hong DG, Lee YS, Cho YL, Cheun SS, et al. Clinical significance of serum albumin levels in pregnancy-related hypertension. J Obstet Gynecol Res. 2010; 36 (6): 1165 – 72.
[23]	Duan Z, Li C, Leung WT, Wu J, Wang M, Ying C, Wang L. Alterations of several serum parameters are Associated with preeclampsia and may be potential markers for the assessment of PE severity. Dis Markers. 2020; 2020: 7815214. doi: 10.1155/2020/7815214.

Cite This Article

Plain Text BibTeX RIS

APA Style

Kinikanwo Green, Collins Amadi. (2021). Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. Journal of Gynecology and Obstetrics, 9(6), 217-223. https://doi.org/10.11648/j.jgo.20210906.16

Copy | Download

ACS Style

Kinikanwo Green; Collins Amadi. Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. J. Gynecol. Obstet. 2021, 9(6), 217-223. doi: 10.11648/j.jgo.20210906.16

Copy | Download

AMA Style

Kinikanwo Green, Collins Amadi. Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. J Gynecol Obstet. 2021;9(6):217-223. doi: 10.11648/j.jgo.20210906.16

Copy | Download

@article{10.11648/j.jgo.20210906.16,
  author = {Kinikanwo Green and Collins Amadi},
  title = {Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome},
  journal = {Journal of Gynecology and Obstetrics},
  volume = {9},
  number = {6},
  pages = {217-223},
  doi = {10.11648/j.jgo.20210906.16},
  url = {https://doi.org/10.11648/j.jgo.20210906.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20210906.16},
  abstract = {Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (pConclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome
AU  - Kinikanwo Green
AU  - Collins Amadi
Y1  - 2021/11/17
PY  - 2021
N1  - https://doi.org/10.11648/j.jgo.20210906.16
DO  - 10.11648/j.jgo.20210906.16
T2  - Journal of Gynecology and Obstetrics
JF  - Journal of Gynecology and Obstetrics
JO  - Journal of Gynecology and Obstetrics
SP  - 217
EP  - 223
PB  - Science Publishing Group
SN  - 2376-7820
UR  - https://doi.org/10.11648/j.jgo.20210906.16
AB  - Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (pConclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.
VL  - 9
IS  - 6
ER  -

Copy | Download

Author Information

Kinikanwo Green

Department of Obstetrics and Gynecology, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Collins Amadi

Department of Chemical Pathology, Rivers State University Teaching Hospital, Port Harcourt, Nigeria

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Kinikanwo Green, Collins Amadi. (2021). Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. Journal of Gynecology and Obstetrics, 9(6), 217-223. https://doi.org/10.11648/j.jgo.20210906.16

Copy | Download

ACS Style

Kinikanwo Green; Collins Amadi. Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. J. Gynecol. Obstet. 2021, 9(6), 217-223. doi: 10.11648/j.jgo.20210906.16

Copy | Download

AMA Style

Kinikanwo Green, Collins Amadi. Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. J Gynecol Obstet. 2021;9(6):217-223. doi: 10.11648/j.jgo.20210906.16

Copy | Download

@article{10.11648/j.jgo.20210906.16,
  author = {Kinikanwo Green and Collins Amadi},
  title = {Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome},
  journal = {Journal of Gynecology and Obstetrics},
  volume = {9},
  number = {6},
  pages = {217-223},
  doi = {10.11648/j.jgo.20210906.16},
  url = {https://doi.org/10.11648/j.jgo.20210906.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20210906.16},
  abstract = {Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (pConclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome
AU  - Kinikanwo Green
AU  - Collins Amadi
Y1  - 2021/11/17
PY  - 2021
N1  - https://doi.org/10.11648/j.jgo.20210906.16
DO  - 10.11648/j.jgo.20210906.16
T2  - Journal of Gynecology and Obstetrics
JF  - Journal of Gynecology and Obstetrics
JO  - Journal of Gynecology and Obstetrics
SP  - 217
EP  - 223
PB  - Science Publishing Group
SN  - 2376-7820
UR  - https://doi.org/10.11648/j.jgo.20210906.16
AB  - Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (pConclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.
VL  - 9
IS  - 6
ER  -

Copy | Download